Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

The advancements in technology and manufacturing processes have allowed the development of new derivatives, biosimilar or advanced improved versions for approved antibodies each year for treatment regimen. There are more than 700 antibody-based molecules that are in different stages of phase I/II/ I...

Descripción completa

Detalles Bibliográficos
Autores principales: Parray, Hilal Ahmed, Shukla, Shivangi, Samal, Sweety, Shrivastava, Tripti, Ahmed, Shubbir, Sharma, Chandresh, Kumar, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255167/
https://www.ncbi.nlm.nih.gov/pubmed/32473573
http://dx.doi.org/10.1016/j.intimp.2020.106639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255167/
https://www.ncbi.nlm.nih.gov/pubmed/32473573
http://dx.doi.org/10.1016/j.intimp.2020.106639

Ejemplares similares